| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bronchiolitis | D001988 | 6 associated lipids |
| Bronchiolitis Obliterans | D001989 | 8 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Chlamydia Infections | D002690 | 7 associated lipids |
| Chromoblastomycosis | D002862 | 2 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Confusion | D003221 | 4 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zullo A et al. | A new highly effective short-term therapy schedule for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848654 |
| Ikeda S et al. | Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683692 |
| Moayyedi P et al. | The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848655 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Romero-Gómez M et al. | Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616169 |
| Cardenas VM et al. | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. | 2006 | Aliment. Pharmacol. Ther. | pmid:16393310 |
| Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
| Thijs JC et al. | Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:8186339 |
| Kamada T et al. | The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12869086 |
| Miehlke S et al. | Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535873 |
| Neri M et al. | Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535876 |
| Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
| Lai KC et al. | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535877 |
| Miehlke S et al. | Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. | 2006 | Aliment. Pharmacol. Ther. | pmid:16842467 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Bruley Des Varannes S et al. | There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472320 |
| Adachi K et al. | Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472321 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472323 |
| Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
| Lane JA et al. | Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. | 2011 | Aliment. Pharmacol. Ther. | pmid:21366634 |
| Sasaki A et al. | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12823156 |
| Fischbach LA et al. | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569109 |
| Gu Q et al. | Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. | 2004 | Aliment. Pharmacol. Ther. | pmid:15352916 |
| Sung JJ et al. | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726384 |
| Pazzi P et al. | Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726385 |
| Harris AW et al. | Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726387 |
| Malfertheiner P et al. | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969088 |
| Azuma T et al. | Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. | 2000 | Aliment. Pharmacol. Ther. | pmid:10807427 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
| Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
| Ahuja V et al. | Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678815 |
| Grübel P and Cave DR | Factors affecting solubility and penetration of clarithromycin through gastric mucus. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678818 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Barth J and Hahne W | Review article: rabeprazole-based therapy in Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849125 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Qasim A and O'Morain CA | Review article: treatment of Helicobacter pylori infection and factors influencing eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849124 |
| Yousfi MM et al. | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8853767 |
| Gisbert JP and Calvet X | Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. | 2011 | Aliment. Pharmacol. Ther. | pmid:21745241 |
| Hawkey CJ et al. | Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12694089 |
| John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
| Villoria A et al. | Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. | 2008 | Aliment. Pharmacol. Ther. | pmid:18644011 |
| Furuta T et al. | Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17697203 |
| Lionetti E et al. | Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:17032283 |
| Laurent J et al. | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683693 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Kim YS et al. | Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. | 2011 | Aliment. Pharmacol. Ther. | pmid:21923713 |
| You JH et al. | Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421876 |
| Leiper K et al. | Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. | 2008 | Aliment. Pharmacol. Ther. | pmid:18315579 |
| De Francesco V et al. | Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113366 |
| Koivisto TT et al. | Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113368 |
| Gisbert JP and Calvet X | Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. | 2011 | Aliment. Pharmacol. Ther. | pmid:22017749 |
| Pellegrini M et al. | Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. | 2005 | Aliment. Pharmacol. Ther. | pmid:16098001 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Gisbert JP et al. | Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971230 |
| Frevel M et al. | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971231 |
| Bigard MA et al. | One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9690730 |
| Bardhan KD et al. | Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692693 |
| Catalano F et al. | Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692702 |
| Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
| Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Rinaldi V et al. | The management of failed dual or triple therapy for Helicobacter pylori eradication. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354202 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Breuer T et al. | Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354204 |
| Wurzer H et al. | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354205 |
| Harris A | H. pylori eradication by LAC. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354216 |
| Osato MS et al. | Comparative efficacy of new investigational agents against Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284777 |
| Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
| Yousfi MM et al. | Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). | 1996 | Aliment. Pharmacol. Ther. | pmid:8871452 |
| Peterson WL et al. | Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791947 |
| Delchier JC et al. | Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791948 |
| Jaup BH and Norrby A | Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791950 |
| Weldon MJ et al. | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791951 |
| Tursi A et al. | Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791952 |
| Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
| Zullo A et al. | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. | 2007 | Aliment. Pharmacol. Ther. | pmid:17539982 |
| Miwa H et al. | Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? | 2003 | Aliment. Pharmacol. Ther. | pmid:12823158 |
| Nista EC et al. | Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569121 |
| Harris AW et al. | Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971302 |
| Moshkowitz M et al. | One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971304 |
| Wang WH et al. | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886046 |
| Laine L et al. | Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971306 |
| Gisbert JP and Pajares JM | Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030945 |